Treatment of Psoriatic Arthritis Affecting the Toes

Initial Treatment Strategy

The European League Against Rheumatism recommends starting with NSAIDs as first-line therapy for controlling joint symptoms and inflammation in patients with mild disease 2, 1, 3
The American College of Rheumatology suggests adding intra-articular glucocorticoid injections for persistently inflamed joints, but avoiding injecting through psoriatic plaques to prevent infection risk 1, 4
The European League Against Rheumatism advises considering initiating a conventional synthetic DMARD (csDMARD) early if poor prognostic factors are present, including structural damage on imaging, elevated inflammatory markers, dactylitis, or nail involvement 1, 5

The European League Against Rheumatism recommends initiating a csDMARD rapidly rather than waiting for NSAID failure 1, 6
Methotrexate is the preferred first-line DMARD when relevant skin involvement coexists with arthritis, with Level B evidence 2, 1, 6
Sulfasalazine or leflunomide are alternatives with Level A evidence for peripheral arthritis 2, 3

The American College of Rheumatology recommends progressing to a TNF inhibitor after failing at least one csDMARD trial defined as treatment for more than 3 months with more than 2 months at standard target dose, unless significant intolerance or toxicity occurs 2, 1
The European League Against Rheumatism suggests considering TNF inhibitors earlier in patients with poor prognostic factors, including polyarticular disease, elevated inflammatory markers, existing joint damage, or diminished quality of life 2, 6
All three TNF inhibitors (etanercept, infliximab, adalimumab) are equally effective for peripheral arthritis and inhibiting radiographic progression, with Level A evidence 2, 3

Dactylitis occurs in 16-48% of PsA cases and represents synovitis, tenosynovitis, and enthesitis with soft-tissue edema, according to the European League Against Rheumatism 7, 8, 9
Acute dactylitis is a clinical indicator of disease severity and warrants more aggressive treatment, as suggested by the American College of Rheumatology 7, 8

Systemic corticosteroids are not recommended for chronic use in psoriasis due to potential post-steroid psoriasis flare and other adverse effects, with Level I evidence, according to the European League Against Rheumatism 2, 5, 10
Local glucocorticoid injections may be used judiciously but systemic therapy should be avoided, as advised by the American College of Rheumatology 1, 10

A patient is considered a treatment failure when, despite therapy for an appropriate duration at adequate dose, they fail to demonstrate acceptable clinical improvement, according to the European League Against Rheumatism 2, 5
DMARD failure is defined as inadequate response after more than 3 months treatment with more than 2 months at standard target dose, as suggested by the American College of Rheumatology 2
Response may be inadequate if there is evidence of progression of joint damage on radiographs, according to the European League Against Rheumatism 2, 5

The primary goal is maximizing health-related quality of life through symptom control, prevention of structural damage, normalization of function, and social participation, as recommended by the American College of Rheumatology 1
Aim for remission or low disease activity through regular disease activity assessment and appropriate therapy adjustment, according to the European League Against Rheumatism 1